Biology of adenovirus and its use as a vector for gene therapy

Human Gene Therapy

Volumn 15, Issue 11, 2004, Pages 1022-1033

  McConnell, Michael J ^a   Imperiale, Michael J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ONCOLYTIC VIRUS; VIRUS DNA;

DNA REPLICATION; GENE EXPRESSION; GENE THERAPY; HELPER CELL; IMMUNE RESPONSE; INTERNALIZATION; LIFE CYCLE; NONHUMAN; REVIEW; VIRUS ADSORPTION; VIRUS ASSEMBLY; VIRUS MORPHOLOGY; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; DNA; GENE EXPRESSION REGULATION, VIRAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MODELS, GENETIC; TRANSCRIPTION, GENETIC;

ADENOVIRIDAE; DNA VIRUSES;

EID: 9244257887     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2004.15.1022     Document Type: Review

References (156)

1. AMALFITANO, A., and CHAMBERLAIN, J.S. (1997). Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: Implications for gene therapy. Gene Ther. 4, 258-263.
2. AMALFITANO, A., BEGY, C.R., and CHAMBERLAIN, J.S. (1996). Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors. Proc. Natl. Acad. Sci. U.S.A. 93, 3352-3356.
3. AMALFITANO, A., HAUSER, M.A., HU, H., SERRA, D., BEGY, C.R., and CHAMBERLAIN, J.S. (1998). Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J. Virol. 72, 926-933.
4. ANSIEAU, S., STROBL, L.J., and LEUTZ, A. (2001). Activation of the Notch-regulated transcription factor CBF1/RBP-Jκ through the 13SE1A oncoprotein. Genes Dev. 15, 380-385.
5. ARMENTANO, D., ZABNER, J., SACKS, C., SOOKDEO, C.C., SMITH, M.P., ST. GEORGE, J.A., WADSWORTH, S.C., SMITH, A.E., and GREGORY, R.J. (1997). Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J. Virol. 71, 2408-2416.
6. BALAMOTIS, M.A., HUANG, K., and MITANI, K. (2004). Efficient delivery and stable gene expression in a hematopoietic cell line using a chimeric serotype 35 fiber pseudotyped helper-dependent adenoviral vector. Virology 324, 229-237.
7. BENEDICT, C.A., NORRIS, P.S., PRIGOZY, T.I., BODMER, J.L., MAHR, J.A., GARNETT, C.T., MARTINON, F., TSCHOPP, J., GOODING, L.R., and WARE, C.F. (2001). Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2. J. Biol. Chem. 276, 3270-3278.
8. BEN-ISRAEL, H., and KLEINBERGER, T. (2002). Adenovirus and cell cycle control. Front. Biosci. 7, d1369-d1395.
9. BENNETT, E.M., BENNINK, J.R., YEWDELL, J.W., and BRODSKY, F.M. (1999). Cutting edge: Adenovirus E19 has two mechanisms for affecting class 1 MHC expression. J. Immunol. 162, 5049-5052.
10. BERK, A.J. (1986). Adenovirus promoters and E1A transactivation. Annu. Rev. Genet. 20, 45-79.
11. BETT, A.J., PREVEC, L., and GRAHAM, F.L. (1993). Packaging capacity and stability of human adenovirus type 5 vectors. J. Virol. 67, 5911-5921.
12. BISCHOFF, J.R., KIRN, D.H., WILLIAMS, A., HEISE, C., HORN, S., MUNA, M., NG, L., NYE, J.A., SAMPSON-JOHANNES, A., FATTAEY. A., and MCCORMICK, F. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376.
13. BROUGH, D.E., HSU, C., KULESA, V.A., LEE, G.M., CANTOLUPO, L.J., LIZONOVA, A., and KOVESDI, I. (1997). Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo. J. Virol. 71, 9206-9213.
14. BRUDER, J.T., JIE, T., MCVEY, D.L., and KOVESDI, I. (1997). Expression of gp19K increases the persistence of transgene expression from an adenovirus vector in the mouse lung and liver. J. Virol. 71, 7623-7628.
15. BURGERT, H.G., MARYANSKI, J.L., and KVIST, S. (1987). "E3/19K" protein of adenovirus type 2 inhibits lysis of cytolytic T lymphocytes by blocking cell-surface expression of histocompatibility class I antigens. Proc. Natl. Acad. Sci. U.S.A. 84, 1356-1360.
16. CARVALHO, T., SEELER, J.S., OHMAN, K., JORDAN, P., PETTERSSON, U., AKUSJARVI, G., CARMO-FONSECA, M., and DEJEAN, A. (1995). Targeting of adenovirus E1A and E4-ORF3 proteins to nuclear matrix-associated PML bodies. J. Cell Biol. 131, 45-56.
17. CEPKO, C.L., and SHARP, P.A. (1982). Assembly of adenovirus major capsid protein is mediated by a nonvirion protein. Cell 31, 407-415.
18. CEPKO, C.L., and SHARP, P.A. (1983). Analysis of Ad5 hexon and 100K ts mutants using conformation-specific monoclonal antibodies. Virology 129, 137-154.
19. CHAKRAVARTI, D., OGRYZKO, V., KAO, H.Y., NASH, A., CHEN, H., NAKATANI, Y., and EVANS, R.M. (1999). A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity. Cell 96, 393-403.
20. CHATTOPADHYAY, D., GHOSH, M.K., MAL, A., and HARTER, M.L. (2001). Inactivation of p21 by E1A leads to the induction of apoptosis in DNA-damaged cells. J. Virol. 75, 9844-9856.
21. CHEN, H.H., MACK, L.M., KELLY, R., ONTELL, M., KOCHANEK, S., and CLEMENS, P.R. (1997). Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc. Natl. Acad. Sci. U.S.A. 94, 1645-1650.
22. CHEN, P., TIAN, J., KOVESDI, I., and BRUDER, J.T. (1998). Interaction of the adenovirus 14.7-kDa protein with FLICE inhibits Fas ligand-induced apoptosis. J. Biol. Chem. 273, 5815-5820.
23. CHESHENKO, N., KROUGLIAK, N., EISENSMITH, R.C., and KROUGLIAK, V.A. (2001). A novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus. Gene Ther. 8, 846-854.
24. CHINNADURAI, G., CHINNADURAI, S., and BRUSCA, J. (1979). Physical mapping of a large-plaque mutation of adenovirus type 2. J. Virol. 32, 623-628.
25. CLEMENS, P.R., KOCHANEK, S., SUNADA, Y., CHAN, S., CHEN, H.H., CAMPBELL, K.P., and CASKEY, C.T. (1996). In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes. Gene Ther. 3, 965-972.
26. CROYLE, M.A., CHIRMULE, N., ZHANG, Y., and WILSON, J.M. (2001). "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J. Virol. 75, 4792-4801.
27. CROYLE, M.A., CHIRMULE, N., ZHANG, Y., and WILSON, J.M. (2002). PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum. Gene Ther. 13, 1887-1900.
28. CURIEL, D.T. (1999). Strategies to adapt adenoviral vectors for targeted delivery. Ann. N.Y. Acad. Sci. 886, 158-171.
29. DAI, Y., SCHWARZ, E.M., GU, D., ZHANG, W.W., SARVETNICK, N., and VERMA, I.M. (1995). Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. U.S.A. 92, 1401-1405.
30. DANTHINNE, X., and IMPERIALE, M.J. (2000). Production of first generation adenovirus vectors: A review. Gene Ther. 7, 1707-1714.
31. DEDIEU, J.F., VIGNE, E., TORRENT, C., JULLIEN, C., MAHFOUZ, I., CAILLAUD, J.M., AUBAILLY, N., ORSINI, C., GUILLAUME, J.M., OPOLON, P., DELAERE, P., PERRICAUDET, M., and YEH, P. (1997). Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J. Virol. 71, 4626-4637.
32. DE JONG, R.N., VAN DER VLIET, P.C., and BRENKMAN, A.B. (2003). Adenovirus DNA replication: Protein priming, jumping back and the role of the DNA binding protein DBP. Curr. Top. Microbiol. Immunol. 272, 187-211.
33. DELLORUSSO, C., SCOTT, J.M., HARTIGAN-O'CONNOR, D., SALVATORI, G., BARJOT, C., ROBINSON, A.S., CRAWFORD, R.W., BROOKS, S.V., and CHAMBERLAIN, J.S. (2002). Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proc. Natl. Acad. Sci. U.S.A. 99, 12979-12984.
34. D'HALLUIN, J.C., MARTIN, G.R., TORPIER, G., and BOULANGER, P.A. (1978a). Adenovirus type 2 assembly analyzed by reversible cross-linking of labile intermediates. J. Virol. 26, 357-363.
35. D'HALLUIN, J.C., MILLEVILLE, M., BOULANGER, P.A., and MARTIN, G.R. (1978b). Temperature-sensitive mutant of adenovirus type 2 blocked in virion assembly: Accumulation of light intermediate particles. J. Virol. 26, 344-356.
36. DIMITROV, T., KRAJCSI, P., HERMISTON, T.W., TOLLEFSON, A.E., HANNINK, M., and WOLD, W.S. (1997). Adenovirus E3-10.4K/14.5K protein complex inhibits tumor necrosis factor-induced translocation of cytosolic phospholipase A2 to membranes. J. Virol. 71, 2830-2837.
37. DMITRIEV, I., KRASNYKH, V., MILLER, C.R., WANG, M., KASHENTSEVA, E., MIKHEEVA, G., BELOUSOVA, N., and CURIEL, D.T. (1998). An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 72, 9706-9713.
38. DOBNER, T., HORIKOSHI, N., RUBENWOLF, S., and SHENK, T. (1996). Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science 272, 1470-1473.
39. DOERFLER, W., and BOHM, P., eds. (2003; 2004). Current Topics in Microbiology and Immunology, Vols. 272 and 273: Adenoviruses: Model and Vectors in Virus-Host Interactions. (Springer-Verlag, Berlin).
40. EDVARDSSON, B., EVERITT, E., JORNVALL, H., PRAGE, L., and PHILIPSON, L. (1976). Intermediates in adenovirus assembly. J. Virol. 19, 533-547.
41. EHRHARDT, A., and KAY, M.A. (2002). A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood 99, 3923-3930.
42. EVANS, J.D., and HEARING, P. (2003). Distinct roles of the adenovirus E4 ORF3 protein in viral DNA replication and inhibition of genome concatenation. J. Virol. 77, 5295-5304.
43. FALLAUX, F.J., KRANENBURG, O., CRAMER, S.J., HOUWELING, A., VAN ORMONDT, H., HOEBEN, R.C., and VAN DER EB, A.J. (1996). Characterization of 911: A new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum. Gene Ther. 7, 215-222.
44. FALLAUX, F.J., BOUT, A., VAN DER VELDE, I., VAN DEN WOLLENBERG, D.J., HEHIR, K.M., KEEGAN, J., AUGER, C., CRAMER, S.J., VAN ORMONDT, H., VAN DER EB, A.J., VALERIO, D., and HOEBEN, R.C. (1998). New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. 9, 1909-1917.
45. FESSLER, S.P., and YOUNG, C.S. (1999). The role of the L4 33K gene in adenovirus infection. Virology 263, 507-516.
46. FINNEN, R.L., BIDDLE, J.F., and FLINT, J. (2001). Truncation of the human adenovirus type 5 L4 33-kDa protein: Evidence for an essential role of the carboxy-terminus in the viral infectious cycle. Virology 289, 388-399.
47. FITZGERALD, J.C., GAO, G.P., REYES-SANDOVAL, A., PAVLAKIS, G.N., XIANG, Z.Q., WLAZLO, A.P., GILES-DAVIS, W., WILSON, J.M., and ERTL, H.C. (2003). A simian replication-defective adenoviral recombinant vaccine to HIV-1 Gag. J. Immunol. 170, 1416-1422.
48. FRESE, K.K., LEE, S.S., THOMAS, D.L., LATORRE, I.J., WEISS, R.S., GLAUNSINGER, B.A., and JAVIER, R.T. (2003). Selective PDZ protein-dependent stimulation of phosphatidylinositol 3-kinase by the adenovirus E4-ORF1 oncoprotein. Oncogene 22, 710-721.
49. FUCHS, M., GERBER, J., DRAPKIN, R., SIF, S., IKURA, T., OGRYZKO, V., LANE, W.S., NAKATANI, Y., and LIVINGSTON, D.M. (2001). The p400 complex is an essential E1A transformation target. Cell 106, 297-307.
50. FUEYO, J., GOMEZ-MANZANO, C., ALEMANY, R., LEE, P.S., MCDONNELL, T.J., MITLIANGA, P., SHI, Y.X., LEVIN, V.A., YUNG, W.K., and KYRITSIS, A.P. (2000). A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19, 2-12.
51. GAGGAR, A., SHAYAKHMETOV, D.M., and LIEBER, A. (2003). CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 9, 1408-1412.
52. GAYNOR, R.B., and BERK, A.J. (1983). Cis-acting induction of adenovirus transcription. Cell 33, 683-693.
53. GLAUNSINGER, B.A., WEISS, R.S., LEE, S.S., and JAVIER, R. (2001). Link of the unique oncogenic properties of adenovirus type 9 E4-ORF1 to a select interaction with the candidate tumor suppressor protein ZO-2. EMBO J. 20, 5578-5586.
54. GOODING, L.R., RANHEIM, T.S., TOLLEFSON, A.E., AQUINO, L., DUERKSEN-HUGHES, P., HORTON, T.M., and WOLD, W.S. (1991). The 10,400- and 14,500-dalton proteins encoded by region E3 of adenovirus function together to protect many but not all mouse cell lines against lysis by tumor necrosis factor. J. Virol. 65, 4114-4123.
55. GOODRUM, F.D., and ORNELLES, D.A. (1998). p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J. Virol. 72, 9479-9490.
56. GORZIGLIA, M.I., KADAN, M.J., YEI, S., LIM, J., LEE, G.M., LUTHRA, R., and TRAPNELL, B.C. (1996). Elimination of both E1 and E2 from adenovirus vectors further improves prospects for in vivo human gene therapy. J. Virol. 70, 4173-4178.
57. GRABLE, M., and HEARING, P. (1990). Adenovirus type 5 packaging domain is composed of a repeated element that is functionally redundant. J. Virol. 64, 2047-2056.
58. GRAHAM, F.L., SMILEY, J., RUSSELL, W.C., and NAIRN, R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-74.
59. GRAVE, L., DREYER, D., DIETERLE, A., LEROY, P., MICHOU, A.I., DODERER, C., PAVIRANI, A., LUSKY, M., and MEHTALI, M. (2000). Differential influence of the E4 adenoviral genes on viral and cellular promoters. J. Gene Med. 2, 433-443.
60. GUSTIN, K.E., and IMPERIALE, M.J. (1998). Encapsidation of viral DNA requires the adenovirus L1 52/55-kilodalton protein. J. Virol. 72, 7860-7870.
61. GUSTIN, K.E., LUTZ, P., and IMPERIALE, M.J. (1996). Interaction of the adenovirus L1 52/55-kilodalton protein with the IVa2 gene product during infection. J. Virol. 70, 6463-6467.
62. HALL, A.R., DIX, B.R., O'CARROLL, S.J., and BRAITHWAITE, A.W. (1998). p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat. Med. 4, 1068-1072.
63. HAMAMORI, Y., SARTORELLI, V., OGRYZKO, V., PURI, P.L., WU, H.Y., WANG, J.Y., NAKATANI, Y., and KEDES, L. (1999). Regulation of histone acetyltransferases p300 and PCAF by the bHLH protein twist and adenoviral oncoprotein E1A. Cell 96, 405-413.
64. HARADA, J.N., and BERK, A.J. (1999). p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J. Virol. 73, 5333-5344.
65. HARDY, S., ENGEL, D.A., and SHENK, T. (1989). An adenovirus early region 4 gene product is required for induction of the infection-specific form of cellular E2F activity. Genes Dev. 3, 1062-1074.
66. HARLOW, E., WHYTE, P., FRANZA, B.R., JR., and SCHLEY, C. (1986). Association of adenovirus early-region 1A proteins with cellular polypeptides. Mol. Cell. Biol. 6, 1579-1589.
67. HASSON, T.B., SOLOWAY, P.D., ORNELLES, D.A., DOERFLER, W., and SHENK, T. (1989). Adenovirus L1 52- and 55-kilodalton proteins are required for assembly of virions. J. Virol. 63, 3612-3621.
68. HAVENGA, M.J., LEMCKERT, A.A., OPHORST, O.J., VAN MEIJER, M., GERMERAAD, W.T., GRIMBERGEN, J., VAN DEN DOEL, M.A., VOGELS, R., VAN DEUTEKOM, J., JANSON, A.A., DE BRUIJN, J.D., UYTDEHAAG, F., QUAX, P.H., LOGTENBERG, T., MEHTALI, M., and BOUT, A. (2002). Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J. Virol. 76, 4612-4620.
69. HAWKINS, L.K., and HERMISTON, T. (2001). Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the E3B region. Gene Ther. 8, 1142-1148.
70. HAWKINS, L.K., JOHNSON, L., BAUZON, M., NYE, J.A., CASTRO, D., KITZES, G.A., YOUNG, M.D., HOLT, J.K., TROWN, P., and HERMISTON, T.W. (2001). Gene delivery from the E3 region of replicating human adenovirus: Evaluation of the 6.7K/gp19K region. Gene Ther. 8, 1123-1131.
71. HEARING, P., SAMULSKI, R.J., WISHART, W.L., and SHENK, T. (1987). Identification of a repeated sequence element required for efficient encapsidation of the adenovirus type 5 chromosome. J. Virol. 61, 2555-2558.
72. HEISE, C., SAMPSON-JOHANNES, A., WILLIAMS, A., MCCORMICK, F., VON HOFF, D.D., and KIRN, D.H. (1997). ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3, 639-645.
73. HONDA, T., SAITOH, H., MASUKO, M., KATAGIRI-ABE, T., TOMINAGA, K., KOZAKAI, I., KOBAYASHI, K., KUMANISHI, T., WATANABE, Y.G., ODANI, S., and KUWANO, R. (2000). The coxsackievirus-adenovirus receptor protein as a cell adhesion molecule in the developing mouse brain. Brain Res. Mol. Brain Res. 77, 19-28.
74. HOWITT, J., ANDERSON, C.W., and FREIMUTH, P. (2003). Adenovirus interaction with its cellular receptor CAR. Curr. Top. Microbiol. Immunol. 272, 331-364.
75. HU, H., SERRA, D., and AMALFITANO, A. (1999). Persistence of an [E1-, polymerase-] adenovirus vector despite transduction of a neoantigen into immune-competent mice. Hum. Gene Ther. 10, 355-364.
76. HUANG, M.M., and HEARING, P. (1989). The adenovirus early region 4 open reading frame 6/7 protein regulates the DNA binding activity of the cellular transcription factor, E2F, through a direct complex. Genes Dev. 3, 1699-1710.
77. ILAN, Y., DROGUETT, G., CHOWDHURY, N.R., LI, Y., SENGUPTA, K., THUMMALA, N.R., DAVIDSON, A., CHOWDHURY, J.R., and HORWITZ, M.S. (1997). Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc. Natl. Acad. Sci. U.S.A. 94, 2587-2592.
78. IMPERIALE, M.J., KAO, H.T., FELDMAN, L.T., NEVINS, J.R., and STRICKLAND, S. (1984). Common control of the heat shock gene and early adenovirus genes: Evidence for a cellular E1A-like activity. Mol. Cell. Biol. 4, 867-874.
79. JAVIER, R., RASKA, K., Jr., MACDONALD, G.J., and SHENK, T. (1991). Human adenovirus type 9-induced rat mammary tumors. J. Virol. 65, 3192-3202.
80. JONES, N., and SHENK, T. (1978). Isolation of deletion and substitution mutants of adenovirus type 5. Cell 13, 181-188.
81. KELKAR, S.A., PFISTER, K.K., CRYSTAL, R.G., and LEOPOLD, P.L. (2004). Cytoplasmic dynein mediates adenovirus binding to microtubules. J. Virol. 78, 10122-10132.
82. KRAJCSI, P., DIMITROV, T., HERMISTON, T.W., TOLLEFSON, A.E., RANHEIM, T.S., VANDE POL, S.B., STEPHENSON, A.H., and WOLD, W.S. (1996). The adenovirus E3-14.7K protein and the E3-10.4K/14.5K complex of proteins, which independently inhibit tumor necrosis factor (TNF)-induced apoptosis, also independently inhibit TNF-induced release of arachidonic acid. J. Virol. 70, 4904-4913.
83. LANG, S.E., and HEARING, P. (2003). The adenovirus E1A oncoprotein recruits the cellular TRRAP/GCN5 histone acetyltransferase complex. Oncogene 22, 2836-2841.
84. LEWIS, A.M., JR., and ROWE, W.P. (1970). Isolation of two plaque variants from the adenovirus type 2-simian virus 40 hybrid population which differ in their efficiency in yielding simian virus 40. J. Virol. 5, 413-420.
85. LEWIS, A.M., JR., BAUM, S.G., PRIGGE, K.O., and ROWE, W.P. (1966a). Occurrence of adenovirus-SV40 hybrids among monkey kidney cell adapted strains of adenovirus. Proc. Soc. Exp. Biol. Med. 122, 214-218.
86. LEWIS, A.M., JR., PRIGGE, K.O., and ROWE, W.P. (1966b). Studies of adenovirus-SV40 hybrid viruses. IV. An adenovirus type 2 strain carrying the infectious SV40 genome. Proc. Natl. Acad. Sci. U.S.A. 55, 526-531.
87. LI, Y., KANG, J., and HORWITZ, M.S. (1998). Interaction of an adenovirus E3 14.7-kilodalton protein with a novel tumor necrosis factor α-inducible cellular protein containing leucine zipper domains. Mol. Cell. Biol. 18, 1601-1610.
88. LIU, Q., and MURUVE, D.A. (2003). Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther. 10, 935-940.
89. LOCHMULLER, H., JANI, A., HUARD, J., PRESCOTT, S., SIMONEAU, M., MASSIE, B., KARPATI, G., and ACSADI, G. (1994). Emergence of early region 1-containing replication-competent adenovirus in stocks of replication-defective adenovirus recombinants (ΔE1 + ΔE3) during multiple passages in 293 cells. Hum. Gene Ther. 5, 1485-1491.
90. LUSKY, M., CHRIST, M., RITTNER, K., DIETERLE, A., DREYER, D., MOUROT, B., SCHULTZ, H., STOECKEL, F., PAVIRANI, A., and MEHTALI, M. (1998). In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J. Virol. 72, 2022-2032.
91. MACK, C.A., SONG, W.R., CARPENTER, H., WICKHAM, T.J., KOVESDI, I., HARVEY, B.C., MAGOVERN, C.J., ISOM, O.W., ROSENGART, T., FALCK-PEDERSEN, E., HACKETT, N.R., CRYSTAL, R.G., and MASTRANGELI, A. (1997). Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum. Gene Ther. 8, 99-109.
92. MANGEL, W.F., BANIECKI, M.L., and McGRATH, W.J. (2003). Specific interactions of the adenovirus proteinase with the viral DNA, an 11-amino-acid viral peptide, and the cellular protein actin. Cell. Mol. Life Sci. 60, 2347-2355,
93. MASTRANGELI, A., HARVEY, B.G., YAO, J., WOLFF, G., KOVESDI, I., CRYSTAL, R.G., and FALCK-PEDERSEN, E. (1996). "Sero-switch" adenovirus-mediated in vivo gene transfer: Circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum. Gene Ther. 7, 79-87.
94. MAUL, G.G. (1998). Nuclear domain 10, the site of DNA virus transcription and replication. Bioessays 20, 660-667.
95. MCCORMICK, F. (2003). Cancer-specific viruses and the development of ONYX-015. Cancer Biol. Ther. 2, S157-S160.
96. MEIER, O., BOUCKE, K., HAMMER, S.V., KELLER, S., STIDWILL, R.P., HEMMI, S., and GREBER, U.F. (2002). Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake. J. Cell Biol. 158, 1119-1131.
97. MIAN, A., MCCORMACK, W.M., JR., MANE, V., KLEPPE, S., NG, P., FINEGOLD, M., O'BRIEN, W.E., RODGERS, J.R., BEAUDET, A.L., and LEE, B. (2004). Long-term correction of ornithine transcarbamylase deficiency by WPRE-mediated overexpression using a helper-dependent adenovirus. Mol. Ther. 10, 492-499.
98. MORAN, E. (1993). DNA tumor virus transforming proteins and the cell cycle. Curr. Opin. Genet. Dev. 3, 63-70.
99. MURUVE, D.A., BARNES, M.J., STILLMAN, I.E., and LIBERMANN, T.A. (1999). Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum. Gene Ther. 10, 965-976.
100. MURUVE, D.A., COTTER, M.J., ZAISS, A.K., WHITE, L.R., LIU, Q., CHAN, T., CLARK, S.A., ROSS, P.J., MEULENBROEK, R.A., MAELANDSMO, G.M., and PARKS, R.J. (2004). Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J. Virol. 78, 5966-5972.
101. NEVINS, J.R. (1995). Adenovirus E1A: Transcription regulation and alteration of cell growth control. Curr. Top. Microbiol. Immunol. 199, 25-32.
102. PALMER, D., and NG, P. (2003). Improved system for helper-dependent adenoviral vector production. Mol. Ther. 8, 846-852.
103. PARKS, R.J., CHEN, L., ANTON, M., SANKAR, U., RUDNICKI, M.A., and GRAHAM, F.L. (1996). A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. U.S.A. 93, 13565-13570.
104. 1/S cyclin/CDK complexes. Oncogene 20, 4793-4806.
105. PASTURE, L., BELALCAZAR, L.M., OKA, K., CELA, R., LEE, B., CHAN, L., and BEAUDET, A.L. (2004). Helper-dependent adenoviral vector-mediated long-term expression of human apolipoprotein A-I reduces atherosclerosis in apo E-deficient mice. Gene 327, 153-160.
106. PEREZ, D., and WHITE, E. (2000). TNF-α signals apoptosis through a bid-dependent conformational change in Bax that is inhibited by E1B 19K. Mol. Cell 6, 53-63.
107. PIERCE, W.E., ROSENBAUM, M.J., EDWARDS, E.A., PECKINPAUGH, R.O., and JACKSON, G.G. (1968). Live and inactivated adenovirus vaccines for the prevention of acute respiratory illness in naval recruits. Am. J. Epidemiol. 87, 237-246.
108. PILDER, S., MOORE, M., LOGAN, J., and SHENK, T. (1986). The adenovirus E1B-55K transforming polypeptide modulates transport or cytoplasmic stabilization of viral and host cell mRNAs. Mol. Cell. Biol. 6, 470-476.
109. QIN, L., DING, Y., PAHUD, D.R., CHANG, E., IMPERIALE, M.J., and BROMBERG, J.S. (1997). Promoter attenuation in gene therapy: Interfevon-γ and tumor necrosis factor-α inhibit transgene expression. Hum. Gene Ther. 8, 2019-2029.
110. QUERIDO, E., BLANCHETTE, P., YAN, Q., KAMURA, T., MORRISON, M., BOIVIN, D., KAELIN, W.G., CONAWAY, R.C., CONAWAY, J.W., and BRANTON, P.E. (2001a). Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev. 15, 3104-3117.
111. QUERIDO, E., MORRISON, M.R., CHU-PHAM-DANG, H., THIRLWELL, S.W., BOIVIN, D., BRANTON, P.E., and MORISSON, M.R. (2001b). Identification of three functions of the adenovirus e4orf6 protein that mediate p53 degradation by the E4orf6-E1B55K complex. J. Virol. 75, 699-709.
112. RAO, L., DEBBAS, M., SABBATINI, P., HOCKENBERY, D., KORSMEYER, S., and WHITE, E. (1992). The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. Proc. Natl. Acad. Sci. U.S.A. 89, 7742-7746.
113. REA, D., HAVENGA, M.J., VAN DEN ASSEM, M., SUTMULLER, R.P., LEMCKERT, A., HOEBEN, R.C., BOUT, A., MELIEF, C.J., and OFFRlNGA. R. (2001). Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J. Immunol. 166, 5236-5244.
114. REYES-SANDOVAL, A., FITZGERALD, J.C., GRANT, R., ROY, S., XIANG, Z.Q., LI, Y., GAO, G.P., WILSON, J.M., and ERTL, H.C. (2004). Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes. J. Virol. 78, 7392-7399.
115. ROTHMANN, T., HENGSTERMANN, A., WHITAKER, N.J., SCHEFFNER, M., and ZUR HAUSEN, H. (1998). Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol. 72, 9470-9478.
116. ROUTES, J.M., RYAN, S., CLASE, A., MIURA, T., KUHL, A., POTTER, T.A., and COOK, J.L. (2000). Adenovirus E1A oncogene expression in tumor cells enhances killing by TNF-related apoptosis-inducing ligand (TRAIL). J. Immunol. 165, 4522-4527.
117. ROWE, W.P., HUEBNER, R.J., GILMORE, L.K., PARROTT, R.H., and WARD, T.G. (1953). Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc. Soc. Exp. Biol. Med. 84, 570-573.
118. SANDIG, V., YOUIL, R., BETT, A.J., FRANLIN, L.L., OSHIMA, M., MAIONE, D., WANG, F., METZKER, M.L., SAVING, R., and CASKEY, C.T. (2000). Optimization of the helper-dependent adenovirus system for production and potency in vivo. Proc. Natl. Acad. Sci. U.S.A. 97, 1002-1007.
119. SARNOW, P., HO, Y.S., WILLIAMS, J., and LEVINE, A.J. (1982). Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell 28, 387-394.
120. SCHAACK, J., GUO, X., HO, W.Y., KARLOK, M., CHEN, C., and ORNELLES, D. (1995). Adenovirus type 5 precursor terminal protein-expressing 293 and HeLa cell lines. J. Virol. 69, 4079-4085.
121. SCHALEY, J., O'CONNOR, R.J., TAYLOR, L.J., BAR-SAGI, D., and HEARING, P. (2000). Induction of the cellular E2F-1 promoter by the adenovirus E4-6/7 protein. J. Virol. 74, 2084-2093.
122. SCHOWALTER, D.B., TUBB, J.C., LIU, M., WILSON, C.B., and KAY, M.A. (1997). Heterologous expression of adenovirus E3-gp19K in an E1a-deleted adenovirus vector inhibits MHC I expression in vitro, but does not prolong transgene expression in vivo. Gene Ther. 4, 351-360.
123. SEGERMAN, A., ATKINSON, J.P., MARTTILA, M., DENNERQUIST, V., WADELL, G., and ARNBERG. N. (2003). Adenovirus type 11 uses CD46 as a cellular receptor. J. Virol. 77, 9183-9191.
124. SHAO, R., HU, M.C., ZHOU, B.P., LIN, S.Y., CHIAO, P.J., VON LINDERN, R.H., SPOHN, B., and HUNG, M.C. (1999). E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of 1κB kinases and nuclear factor κB activities. J. Biol. Chem. 274, 21495-21498.
125. + cells by a retargeted adenovirus vector. J. Virol. 74, 2567-2583.
126. SHENK, T. (1996). Adenoviridae: The viruses and their replication. In Virology. B.N. Fields, D.M. Knipe, and P.M. Howley, eds. (Lippincott-Raven, New York) pp. 2111-2148.
127. SHISLER, J., YANG, C., WALTER, B., WARE, C.F., and GOODING, L.R. (1997). The adenovirus E3-10.4K/14.5K complex mediates loss of cell surface Fas (CD95) and resistance to Fas-induced apoptosis. J. Virol. 71, 8299-8306.
128. SHTRICHMAN, R., SHARF, R., BARR, H., DOBNER, T., and KLEINBERGER, T. (1999). Induction of apoptosis by adenovirus E4orf4 protein is specific to transformed cells and requires an interaction with protein phosphatase 2A. Proc. Natl. Acad. Sci. U.S.A. 96, 10080-10085.
129. SIRENA, D., LILIENFELD, B., EISENHUT, M., KALIN, S., BOUCKE, K., BEERLI, R.R., VOGT, L., RUEDL, C., BACHMANN, M.F., GREBER, U.F., and HEMMI, S. (2004). The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J. Virol. 78, 4454-4462.
130. + T cells upon Stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber. Cancer Gene Ther. 11, 227-236.
131. STEINWAERDER, D.S., CARLSON, C.A., and LIEBER, A. (1999). Generation of adenovirus vectors devoid of all viral genes by recombination between inverted repeats. J. Virol. 73, 9303-9313.
132. STEVENS, J.L., CANTIN, G.T., WANG, G., SHEVCHENKO, A., and BERK, A.J. (2002). Transcription control by E1A and MAP kinase pathway via Sur2 mediator subunit. Science 296, 755-758.
133. STEWART, P.L., CHIU, C.Y., HUANG, S., MUIR, T., ZHAO, Y., CHAIT, B., MATHIAS, P., and NEMEROW, G.R. (1997). Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization, EMBO J. 16, 1189-1198.
134. STRACKER, T.H., CARSON, C.T., and WEITZMAN, M.D. (2002). Adenovirus oncoproteins inactivate the Mre11-Rad50-NBS1 DNA repair complex. Nature 418, 348-352.
135. SUNDARARAJAN, R., CUCONATI, A., NELSON, D., and WHITE, E. (2001). Tumor necrosis factor-α induces Bax-Bak interaction and apoptosis, which is inhibited by adenovirus E1B 19K. J. Biol. Chem. 276, 45120-45127.
136. TAUBER, B., and DOBNER, T. (2001). Adenovirus early E4 genes in viral oncogenesis. Oncogene 20, 7847-7854.
137. TOLLEFSON, A.E., RYERSE, J.S., SCARIA, A., HERMISTON, T.W., and WOLD, W.S. (1996a), The E3-11,6-kDa adenovirus death protein (ADP) is required for efficient cell death: Characterization of cells infected with adp mutants. Virology 220, 152-162.
138. TOLLEFSON, A.E., SCARIA, A., HERMISTON, T.W., RYERSE, J.S., WOLD, L.J., and WOLD, W.S. (1996b). The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J. Virol. 70, 2296-2306.
139. TOLLEFSON, A.E., TOTH, K., DORONIN, K., KUPPUSWAMY, M., DORONINA, O.A., LICHTENSTEIN, D.L., HERMISTON, T.W., SMITH, C.A., and WOLD, W.S. (2001). Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins. J. Virol. 75, 8875-8887.
140. TROTMAN, L.C., MOSBERGER, N., FORNEROD, M., STIDWILL, R.P., and GREBER, U.F. (2001). Import of adenovirus DNA involves the nuclear pore complex receptor CAN/Nup214 and histone H1. Nat. Cell Biol. 3, 1092-1100.
141. UMANA, P., GERDES, C.A., STONE, D., DAVIS, J.R., WARD, D., CASTRO, M.G., and LOWENSTEIN, P.R. (2001). Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. Nat. Biotechnol. 19, 582-585.
142. VELLINGA, J., RABELINK, M.J., CRAMER, S.J., VAN DEN WOLLENBERG, D.J., VAN DER MEULEN, H., LEPPARD, K.N., FALLAUX, F.J., and HOEBEN, R.C. (2004). Spacers increase the accessibility of peptide ligands linked to the carboxyl terminus of adenovirus minor capsid protein IX. J. Virol. 78, 3470-3479.
143. VIGNE, E., MAHFOUZ, I., DEDIEU, J.F., BRIE, A., PERRICAUDET, M., and YEH, P. (1999). RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J. Virol. 73, 5156-5161.
144. WALTERS, R.W., FREIMUTH, P., MONINGER, T.O., GANSKE, I., ZABNER, I., and WELSH, M.I. (2002). Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing virus escape. Cell 110, 789-799.
145. WANG, Q., GREENBURG, G., BUNCH, D., PARSON, D., and FINER, M.H. (1997). Persistent transgene expression in mouse liver following in vivo gene transfer with a ΔE1/ΔE4 adenovirus vector. Gene Ther. 4, 393-400.
146. WICKHAM, T.J. (2000). Targeting adenovirus. Gene Ther. 7, 110-114.
147. WICKHAM, T.J., CARRION, M.E., and KOVESDI, I. (1995). Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. Gene Ther. 2, 750-756.
148. WODRICH, H., GUAN, T., CINGOLANI, G., VON SEGGERN, D., NEMEROW, G., and GERACE, L. (2003). Switch from capsid protein import to adenovirus assembly by cleavage of nuclear transport signals. EMBO J. 22, 6245-6255.
149. XI, Q., CUESTA, R., and SCHNEIDER, R.I. (2004). Tethering of eIF4G to adenoviral mRNAs by viral 100k protein drives ribosome shunting. Genes Dev. 18, 1997-2009.
150. YANG, Y., NUNES, F.A., BERENCSI, K., FURTH, E.E., GÖNCZÖL, E., and WILSON, J.M. (1994a). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 91, 4407-4411.
151. YANG, Y., NUNES, F.A., BERENCSI, K., GONCZOL, E., ENGELHARDT, J.F., and WILSON, J.M. (1994b). Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat. Genet. 7, 362-369.
152. YANG, Y., LI, Q., ERTL, H.C., and WILSON, J.M. (1995). Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69, 2004-2015.
153. ZHANG, W., and IMPERIALE, M.J. (2000). Interaction of the adenovirus IVa2 protein with viral packaging sequences. J. Virol. 74, 2687-2693.
154. ZHANG, W., and IMPERIALE, M.J. (2003). Requirement of the adenovirus IVa2 protein for virus assembly. J. Virol. 77, 3586-3594.
155. ZHANG, W., LOW, J.A., CHRISTENSEN, J.B., and IMPERIALE, M.J. (2001). Role
156. ZOU, W., LUO, C., ZHANG, Z., LIU, J., GU, J., PEI, Z., QIAN, C., and LIU, X. (2004). A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene 23, 457-464.